| High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 20801853 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: Many observational prospective studies have confirmed the inverse relationship between high-density lipoprotein (HDL) cholesterol and coronary heart disease. However, the potential benefit of the pharmacological increase in HDL cholesterol has not been clearly demonstrated. Moreover, in some interventions an increase in total mortality has been reported. OBJECTIVE: The objective of this meta-analysis was to determine the relationship between HDL cholesterol increase and non-cardiovascular mortality in randomised trials. DATA SOURCES: Authors searched Medline up to December 2008. STUDY SELECTION: Four reviewers identified randomised trials in which, through different types of interventions, HDL cholesterol increase in the treatment group was >4% compared to control group, both groups reported separately non-cardiovascular mortality and the duration of the study was, at least, one year. DATA EXTRACTION: Data of HDL cholesterol concentrations and deaths were collected as they appeared in the original studies. If necessary, reviewers calculated data by using trial information. RESULTS: Meta-regression analysis included 44 articles corresponding to 107 773 participants. Analysis showed an association between HDL cholesterol increase and non-cardiovascular mortality (p=0.023), however, the correlation disappeared when we excluded the ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerosis Events) trial from the analysis (p=0.972). CONCLUSIONS: Meta-regression analysis results suggest that increases in HDL cholesterol up to 40% are not associated with higher non-cardiovascular death. The increase in adverse events observed in some trials where HDL cholesterol was raised in large amounts could be related with the drug mechanisms more than the HDL cholesterol increase itself. |
| | |
Authors:
|
Elena Burillo; Eva Maria Andres; Rocio Mateo-Gallego; Sarah Fiddyment; Estibaliz Jarauta; Ana Cenarro; Fernando Civeira |
Related Documents
:
|
8579543 - Management of low hdl cholesterol. 18311663 - Pharmacological therapies for raising hdl cholesterol beyond synthetic small molecules. 20630233 - Effect of dietary crude protein modification on ammonia and nitrous oxide concentration... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Heart (British Cardiac Society) Volume: 96 ISSN: 1468-201X ISO Abbreviation: Heart Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-30 Completed Date: 2010-10-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602087 Medline TA: Heart Country: England |
Other Details:
|
Languages: eng Pagination: 1345-51 Citation Subset: AIM; IM |
Affiliation:
|
Laboratorio de Investigación Molecular, Hospital Universitario Miguel Servet, Zaragoza, Spain. eburilloi.iacs@aragon.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
adverse effects*,
therapeutic use Cardiovascular Diseases / prevention & control* Cholesterol, HDL / blood* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects, therapeutic use Mortality* Randomized Controlled Trials as Topic Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| Comments/Corrections | |
Comment In:
|
Heart. 2010 Sep;96(17):1339-40
[PMID:
20801851
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transradial access for primary percutaneous coronary intervention: the next standard of care?
Next Document: Quantification of lumen stenoses with known dimensions by conventional angiography and computed tomo...